Baidina T V, Trushnikova T N, Danilova M A
Federal State Budgetary Educational Institution of Higher Education 'Academician Ye.A. Vagner Perm State Medical University of Ministry of Healthcare of the Russian Federation, Moscow, Russia.
Zh Nevrol Psikhiatr Im S S Korsakova. 2018;118(8. Vyp. 2):77-81. doi: 10.17116/jnevro201811808277.
To study the dynamics of anxiety-depressive disorders and peripheral blood serotonin in patients with multiple sclerosis (MS) during interferon-ß (IFN-ß) therapy.
The level of anxiety and depression in 227 MS patients was measured by psychometric testing at baseline and during treatment. The concentration of serotonin in serum of patients was determined by enzyme immunoassay.
The presence of emotional disorders in patients with MS was confirmed. Their relationship with personality characteristics of the patient, the course of the disease and social status was shown. The level of humoral serotonin was lower in patients with MS. The relationship between the serotonergic system deficiency in patients with MS and anxiety disorders was shown. Interferon-induced depression was not associated with serotonin metabolism. It is a multifactor condition influenced by the patient's initial emotional level, personality characteristics, psychological reaction to therapy and the unfavorable dynamics of the disease.
IFN-β does not appear to induce depression in MS patients.
研究多发性硬化症(MS)患者在干扰素-β(IFN-β)治疗期间焦虑抑郁障碍及外周血血清素的动态变化。
对227例MS患者在基线期及治疗期间通过心理测试测量焦虑和抑郁水平。采用酶免疫分析法测定患者血清中血清素的浓度。
证实MS患者存在情绪障碍。显示了其与患者个性特征、病程及社会地位的关系。MS患者体液血清素水平较低。显示了MS患者血清素能系统缺陷与焦虑障碍之间的关系。干扰素诱导的抑郁与血清素代谢无关。它是一种多因素状况,受患者初始情绪水平、个性特征、对治疗的心理反应及疾病的不利动态变化影响。
IFN-β似乎不会在MS患者中诱发抑郁。